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ORIGINAL ARTICLE
YGLF motif in the Kaposi sarcoma herpes virus G-protein-
coupled receptor adjusts NF-kB activation and paracrine actions
S Azzi1,2,3,8, SS Smith1,2,3,8, J Dwyer1,2,3, HM Leclair1,2,3, C Alexia4,5,6, JK Hebda1,2,3, N Dupin3,7, N Bide`re4,5,6 and J Gavard1,2,3
Kaposi sarcoma (KS) and primary effusion lymphoma (PEL) are two pathologies associated with KS herpes virus (KSHV/HHV-8)
infection. KSHV genome contains several oncogenes, among which, the viral G-protein-coupled receptor (vGPCR open reading
frame 74) has emerged as a major factor in KS pathogenicity. Indeed, vGPCR is a constitutively active receptor, whose expression is
sufﬁcient to drive cell transformation in vitro and tumour development in mice. However, neither the role of vGPCR in KSHV-
infected B-lymphocytes nor the molecular basis for its constitutive activation is well understood. Here, we show that vGPCR
expression contributes to nuclear factor-kB (NF-kB)-dependent cellular survival in both PEL cells and primary B cells from
HIV-negative KS patients. We further identiﬁed within vGPCR an AP2 consensus binding motif, Y326GLF, that directs its localization
between the plasma membrane and clathrin-coated vesicles. The introduction of a mutation in this site (Y326A) increased NF-kB
activity and proinﬂammatory cytokines production. This correlated with exacerbated morphological rearrangement, migration and
proliferation of non-infected monocytes. Collectively, our work raises the possibility that KSHV-infected B-lymphocytes use vGPCR to
impact ultimately the immune response and communication within the tumour microenvironment in KSHV-associated pathologies.
Oncogene advance online publication, 2 December 2013; doi:10.1038/onc.2013.503
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INTRODUCTION
Kaposi sarcoma (KS) composes a class of heterogeneous pseudo-
endothelial inﬂammatory tumours. These potentially malignant,
widespread lesions are typically found in the skin, oral cavity, lymph
nodes and visceral organs. Five epidemiologic subtypes of KS have
been described: classic from the Mediterranean, Middle Eastern and
Eastern European areas; endemic in subequatorial Africa; iatrogenic
in immunosuppressed transplant patients; epidemic in AIDS-
suffering patients; and rare in HIV-negative men who have sex
with men.1–3 Despite a reduction in incidence due to highly active
antiretroviral therapies, KS remains one of the most common AIDS-
associated malignancies.2 This disease is caused by the KS herpes
virus (KSHV/human herpes virus 8, HHV-8), and still remains
incurable.4–6 Besides KS, KSHV is linked to two aggressive
lymphoproliferative disorders that affect the B-lymphocyte
population, primary effusion lymphomas (PEL) and multicentric
Castleman disease.3,7–9 Currently, the only treatment available for
PEL is a combination of chemotherapy and antiretroviral therapy in
HIV-positive patients, with a median survival of 6 months.9
KSHV-associated lymphomas, like most non-Hodgkin’s lympho-
mas, have developed a profound addiction to nuclear factor-kB
(NF-kB) transcription factors. Indeed, abrogation of constitutive
NF-kB activity is toxic for PEL in vitro and in mouse xenograft
models.10–12 Furthermore, NF-kB activation has also been
proposed to transform endothelial cells and to convey paracrine
transformation in models of KS, both in vitro and in vivo.13–16
Among the proteins encoded by the KSHV, the homologue of
FADD-like interleukin (IL)-1b-converting enzyme (FLICE/caspase-8)
inhibitory protein (vFLIP, also known as K13) is a pivotal mediator
of aberrant NF-kB activation.11,17 Indeed, vFLIP binds and activates
the IkB kinase complex, which phosphorylates the NF-kB inhibitor
IkBa to precipitate its proteasomal degradation, thereby allowing
NF-kB nuclear translocation.18,19 Although transgenic mouse
models have clearly established that forced vFLIP expression
increases lymphoma incidence through uncontrolled NF-kB
activation, vFLIP remains insufﬁcient to fully recapitulate PEL
phenotypes and fails to initiate KS-like lesions in animal
models.20–24 Therefore, it is tempting to speculate that vFLIP
cooperates with other KSHV open reading frames (ORFs) and the
host in the course of both sarcomagenesis and lymphomagenesis.
The ORF74, which encodes for a viral G-protein-coupled
receptor (vGPCR), has emerged as an appealing candidate for
oncogenic abilities of KSHV. vGPCR, a homologue of the human
chemokine receptor CXCR2, harbours multiple point mutations,
which render it constitutively active.25–27 vGPCR is believed to be a
key driver of KS, as it exhibits tumour-initiating and -transforming
potential.20,28–30 Indeed, vGPCR elicits survival, proliferation and
migration in many cell models and signals through various
molecular cascades, including the NF-kB and phosphatidylinositol
3-kinase/mammalian target of rapamycin pathways.13,16,30–33
Moreover, vGPCR-directed NF-kB activation results in the
secretion of proinﬂammatory cytokines that might be involved
in paracrine communication.16,34,35 Interestingly, vGPCR has also
been shown to contribute to immune escape,36 suggesting that
this viral oncogene occupies strategic positions in the
development of KSHV-related malignancies.
Although vGPCR-mediated control of NF-kB activation in
pseudo-endothelial tumours and KS is well documented, whether
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its signalling activity is involved in B-lymphocyte homeostasis is
largely unknown. Here, we provide evidence that vGPCR weighs
into the regulation of the constitutive NF-kB activation and cell
survival of both circulating primary B-lymphocytes in a lymphoma-
free context and PEL cells. We further identify an AP2 binding
motif (Y326GLF) within the C terminus domain of vGPCR, which
ensures its ability to ﬁne-tune NF-kB activation and paracrine
actions.
RESULTS
vGPCR drives NF-kB activation in primary B cells from KS patients
Although vGPCR is sufﬁcient to initiate KS when expressed in the
endothelial compartment,37 its role in KSHV-infected circulating
cells remains poorly documented. We ﬁrst asked whether vGPCR
expression could be involved in the homeostasis of primary B cells
from KS patients, in a lymphoma-free context. To this end, vGPCR
expression was examined by ﬂow cytometry in B-lymphocytes
(CD19), T-lymphocytes (CD3), monocytes (CD11) and
macrophages (CD14) from peripheral blood mononuclear cells
(PBMCs) from HIV-negative KS patients (Table 1). vGPCR was
detected, independently of KS stages and viremia, in CD19-, CD11-
and CD14-positive cells, but was absent from CD3-positive cells.
Therefore, these data discriminate KSHV-infected circulating cell
populations (i.e. positive B cells, macrophages and monocytes
versus negative T cells) (Supplementary Table S1, Figure 1a and
Supplementary Figure S1). The KSHV products, vGPCR, LNA (late-
associated nuclear antigen) and RTA (replication and transcription
activator), were present both in the CD19-positive fraction within
total PBMCs and in puriﬁed CD19-positive cells (Figure 1b). Of
note, the level of expression of latent and lytic KSHV
products, namely LNA, vGPCR and RTA, was not altered when
the CD19-positive cell population was isolated and cultured for 3
days (Figure 1c).
vGPCR can activate the NF-kB transcription factor, which in turn
is known to modulate lymphoproliferation in KSHV-infected
cells.12,16 We therefore explored if the same was true in KSHV-
infected primary B cells. First, levels of IkBa phosphorylation were
signiﬁcantly higher in the KSHV-positive, CD19-positive cell
population, indicative of increased NF-kB activity (Figures 1d
and e). Next, to determine its impact on IkBa phosphorylation,
vGPCR was silenced in total or puriﬁed CD19-positive PBMCs from
KS patients. Reduction in vGPCR expression correlated with
decreased levels of phosphorylated IkBa, albeit LNA expression
levels were not modiﬁed (Figure 1f). In addition, vGPCR silencing
drove cell death in puriﬁed CD19-positive PBMCs (Figure 1g).
Collectively, our data suggest that vGPCR contributes, at least
partially, to NF-kB activation and survival of primary B cells from
KS patients, even in the absence of lymphoproliferative disorders.
vGPCR contributes to the survival of NF-kB-dependent KSHV-
infected PEL
PEL are characterized by a profound addiction to aberrant
activation of NF-kB transcription factors.38 However, whether
vGPCR participates in this process remains unclear. We ﬁrst took
advantage of PEL-derived human cell lines, namely BC1, BC3,
BCBL1 and CRO/AP6, which exhibited high levels of both lytic and
latent KSHV-encoded gene expression at the RNA levels, when
compared with those of KSHV-negative NF-kB-independent
Burkitt’s BJAB lymphoma cells (Figure 2a). As expected, phorbol
12-myristate 13-acetate treatment further enhanced lytic gene
expression in these cell lines (Figure 2b). Flow cytometry analysis
revealed that vGPCR was signiﬁcantly expressed in PEL lines
(Supplementary Table S2 and Figure 2c). Notably, vGPCR was
found coexpressed in either LNA- or RTA-positive cells, suggesting
Table 1. Clinical data of KS patients
KS patients Age (years) Gender HIV status Type of KS Krigel classification CD4 count (cells per mm3) HHV-8 viremia (copies per ml)
Patient 1 52 M Negative Endemic IV 352 þ (2400)
Patient 2 67 M Negative Classic II 379 þ (40)
Patient 3 81 M Negative Classic II 485 Negative
Patient 4 63 M Negative Iatrogenic IV N/A þ (300)
Patient 5 58 M Negative Endemic III 578 Negative
Patient 6 N/A M Negative Classic I N/A ULD
Patient 7 77 M Negative Classic II 621 þ (1200)
Patient 8 82 M Negative Classic I 748 þ (1000)
Patient 9 57 M Negative Iatrogenic IV 451 þ (NQ)
Patient 10 69 F Negative Endemic Remission 1200 ULD
Abbreviations: KSHV/HHV-8, Kaposi sarcoma herpes virus; KS, Kaposi sarcoma; N/A, not available; NQ, not quantifiable; PBMC, peripheral blood mononuclear
cell; ULD, under the limit of detection. Clinical information of HIV-negative, KSHV-positive patients from whom PBMCs were isolated.
Figure 1. vGPCR drives NF-kB activation in primary B cells from KS patients. (a) PBMCs from KS patients (KSHV-positive) and healthy donors
(KSHV-negative) were isolated and the expression of vGPCR was evaluated in CD19-, CD11-, CD3- and CD14-positive cell fractions by flow
cytometry. Representative histograms are shown. Dashed histograms correspond to the isotype-matched control and grey histograms show
vGPCR staining. (b) LNA, vGPCR and RTA total expression was examined in CD19-positive cell fractions from KSHV-positive PBMCs or in
purified CD19-positive cells. Dashed histograms correspond to the isotype-matched control and grey histograms show antibody staining.
(c) Latent and lytic viral products expression was examined by reverse transcription–PCR (RT–PCR) and flow cytometry (10 000 events) in
CD19-positive cells at day 0 and day 3 postpurification. (d) pIkBa expression was examined in CD19-positive cell fractions from KSHV-negative
and -positive PBMCs. Dashed histograms correspond to the isotype-matched control and grey histograms show antibody (Ab) staining
(1 000 000 events). (e) Mean fluorescence intensity (MFI, 1 000 000 events) for patient (KSHV-positive, n¼ 7) and control (KSHV-negative , n¼ 3)
samples were analysed using the PRISM statistical software: vGPCR (P¼ 0.0027), LNA (P¼ 0.0018) and pIkBa (P¼ 0.0017). (f ) PBMCs from KS
patients were isolated and transfected with either non-silencing duplexes sequence (sic) or vGPCR siRNA (si no. 3). Representative samples are
shown. CD19-positive cell fraction of total PBMCs was analysed 72 h post-transfection by flow cytometry (upper panel). Alternatively, CD19-
positive cells were purified before transfection (lower panel). Dashed histograms correspond to the isotype-matched control (Ig), grey and
black histograms show antibody staining. (g) Cell survival in the purified CD19-positive cell population was assessed by flow cytometry, with
DIOC6 staining (10 000 events). The percentage of DIOC6 stained cells is indicated. Data were normalised to cells nucleofected with the
control siRNA (sic). Each panel is representative of three independent experiments.
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Figure 2. vGPCR contributes to the survival of NF-kB-dependent KSHV-infected BC3 PEL. (a) Latent and lytic gene expression levels were
examined by reverse transcription–PCR (RT–PCR) in KSHV-infected PEL-derived cell lines (BC1, BC3, BCBL1 and CroAP/6). KSHV-negative BJAB
cells were used as a negative control. (b) vGPCR and RTA expression levels were examined by RT–PCR in BC1 and BC3 cell lines treated or not
with phorbol 12-myristate 13-acetate (10 ng/ml, 48 h). (c) BC1, BC3, BCBL1 and CroAP/6 were analysed by flow cytometry for surface vGPCR
expression. Dashed histograms correspond to the isotype-matched control and grey histograms show vGPCR staining (10 000 events). (d)
Latent and lytic viral products total expression was analysed in BC3 cells by flow cytometry. Dot plots show double staining of LNA/vGPCR and
RTA/vGPCR (10 000 events). (e) vGPCR, LNA and pIkBa total expression were detected by flow cytometry in BC3 and BJAB cells. Dashed
histograms correspond to the isotype-matched control (Ig) and grey histograms show antibody staining (10 000 events). (f–l) BC3 cells were
transfected with vGPCR siRNA sequences (nos. 1 and 3) and processed 72 h later. Non-silencing duplexes sequence (sic) was used as a control.
(f ) siRNA efficiency was estimated by flow cytometry (10 000 events). (g) The effect of vGPCR silencing on proliferation of BC3 cells was
analysed by the MTT assay. Values were normalised to sic-treated cells and expressed as a mean±s.d. of three independent experiments. (h)
Cell survival was determined by measuring the mitochondrial potential using DIOC6 probe in flow cytometry (10 000 events). Data were
normalised to cells nucleofected with the control siRNA (sic). (i) The expression of the cleaved form of caspase-3 was determined in LNA-
negative and LNA-positive BC3 cells using flow cytometry. Dashed histograms correspond to the isotype-matched control (Ig), grey and black
histograms show antibody staining (10 000 events). (j–l) The levels of pIkBa, pp65, total IkBa and total p65 were determined by western blots
and the expression of vGPCR, LNA and pIkBa by flow cytometry. Dashed histograms correspond to the isotype-matched control (Ig), grey and
black histograms show antibody staining (10 000 events). Each panel is representative of three independent experiments.
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that vGPCR can be detected in cells expressing latent and lytic
markers (Figure 2d). This is reminiscent of the situation of infected
lymphatic endothelial cells that exhibit a mixed latent/lytic
programme.39
Paralleling our observations in B cells isolated from KS patients,
PEL lines were characterized by phosphorylation of both IkBa and
p65 (Figure 2e and Supplementary Figure S2). In addition,
treatment with the IkB kinase inhibitor BMS-34554140 selectively
hampered PEL propagation (Supplementary Figure S2). To next
determine its impact on PEL survival, vGPCR expression was
silenced with two individual small interfering RNA (siRNA)
sequences (Figure 2f). Interestingly, reducing vGPCR levels
restrained PEL expansion and increased cell death, as illustrated
by diminished mitochondrial activity in an MTT viability assay,
reduced mitochondrial transmembrane potential as measured
with a DIOC6 probe and the appearance of cleaved form of
caspase-3 staining (Figures 2g–i). Interestingly, this caspase-3
processing was restrained to LNA-positive cells (Figure 2i).
Furthermore, we found that knocking down vGPCR in PEL
signiﬁcantly reduced NF-kB reporter activity, as well as IkBa and
p65 phosphorylation (Figures 2j–l and Supplementary Figures S3
and S4). In contrast, no obvious changes in LNA expression were
observed in vGPCR-knockdown cells (Figure 2k). To deﬁne the
relative contribution of vGPCR and vFLIP to the aberrant NF-kB
activity in PEL, their expression levels were reduced with siRNA in
BC3 cells and the phosphorylation of IkBa was evaluated by ﬂow
cytometry (Supplementary Figure S4). In both cases, the overall
IkBa phosphorylation was decreased, albeit more pronounced
when vFLIP was knocked down. Interestingly, this was further
aggravated when both vFLIP and vGPCR were silenced. Lastly,
enforced expression in HEK-293T cells of wild-type vGPCR, but not
of R143A, a mutant unable to activate NF-kB, further enhanced
vFLIP-induced NF-kB activation (Supplementary Figure S4). This
argues for a basal activation of NF-kB through vGPCR, indepen-
dently of vFLIP mode of action. Collectively, our results suggest
that vGPCR and vFLIP operate independently to ensure the
constitutive activation of NF-kB activation in KSHV-infected PEL
cells and their continued survival.
vGPCR interacts within clathrin-coated vesicle components and
YGLF motif governs vGPCR distribution
GPCR localization at the plasma membrane is tightly regulated by
vesicular trafﬁcking to prevent aberrant signalling.41 For instance,
CXCR2, the closest human homologue of vGPCR, is rapidly
internalized upon chemokine stimulation (Figure 3a). However,
vGPCR was found both at the cell surface and in an internal
compartment (Figures 3a and b and Supplementary Figure S5). In
silico analysis of vGPCR and CXCR2 sequences unveiled that vGPCR
exclusively harbours a classical AP2 binding motif (Y326GLF) in its
C-terminal tail. We ﬁrst explored the functionality of this motif in
PEL cells. First, confocal analysis and immunoprecipitation
experiments showed that vGPCR constitutively bound clathrin-
coated vesicle (CCV) components, including AP2a, EPS15 and
clathrin heavy chain (Figures 3b and c). Accordingly, a GST pull-
down assay, conducted using either GST-vGPCR321–342 or GST-
CXCR2321–360 C-tails as bait, demonstrated that vGPCR speciﬁcally
interacted with CCV components (Figure 3d). We then investi-
gated whether the loss of vesicular trafﬁcking would result in the
retention of vGPCR at the plasma membrane. To this end, both
siRNA against AP2a and a dominant-negative EPS15 mutant
(EPS15dn) were used to block CCV formation and trafﬁcking in
endogenous (PEL cells; Figure 3e) and ectopic (vGPCR-transfected
HeLa cells; Figures 3f and g) systems. As hypothesized, silencing
AP2a led to an accumulation of vGPCR exposed at the plasma
membrane (Figure 3e). Similarly, when overexpressed, vGPCR was
found to accumulate in AP2a-positive vesicular structures. Like-
wise, while total vGPCR levels remained unchanged, its surface
expression was increased in EPS15dn-transfected cells (Figures 3f
and g). Collectively, this suggests that a fraction of vGPCR is not
available at the plasma membrane, but rather constitutively
trafﬁcs within CCV.
Next, we generated an AP2 binding mutant (Y326A) to
determine whether the AP2 binding site coordinates vGPCR
trafﬁcking and localization. Although both wild-type (WT) and
mutant (YA) constructs were expressed at similar levels in HeLa
cells, only WT vGPCR co-immunoprecipitated with AP2a,
demonstrating that the YA mutant is unable to bind to the AP2
complex (Figure 3h). Furthermore, ﬂow cytometry analysis
revealed that YA vGPCR surface staining was higher than WT
vGPCR (Figure 3i). vGPCR movements were then tracked using an
antibody uptake assay (Figures 3j and k). Although both were
expressed at the plasma membrane, YA vGPCR distinguished
from WT, as it barely accumulated in internal vesicles (Figures 3j
and k). This suggests that basal vGPCR internalization is
restrained in the YA mutant. Our results thus support the notion
that the YGLF motif is required for vGPCR uptake into CCV, and
therefore proper trafﬁcking.
Abrogation of the YGLF motif alters NF-kB activation and vGPCR
paracrine actions
We next tested whether the YGLF motif could also inﬂuence
vGPCR-mediated NF-kB signalling activity. In HeLa cells, ectopic
YA vGPCR triggered higher phosphorylation of IkBa when
compared with WT vGPCR (Figure 4a). Moreover, the YA mutation
markedly boosted the ability of vGPCR to activate NF-kB in a
gene reporter assay (Figure 4b). To further characterize the
functional effects of YA vGPCR expression, we next evaluated its
paracrine actions on non-infected cells. Because NF-kB
activation is strongly associated with enhanced transcription of
key immune response-associated cytokines, we ﬁrst checked the
mRNA levels of IL-6, IL-8, IL-12a, IL-15 and tumor growth factor-b.
YA vGPCR expression signiﬁcantly increased the levels of IL-6, IL-8
and IL-15, whereas decreasing tumor growth factor-b (Figure 4c).
To examine YA-mediated paracrine activity, conditioned
media (CM) prepared from cells expressing either WT or YA
vGPCR were tested on the KSHV-negative THP1 monocytes.
Phosphorylation of IkBa was enhanced in THP1 cells treated
with CM from YA-transfected cells when compared with either
control or WT-derived CM (Figure 4d). In agreement, YA-CM
signiﬁcantly increased NF-kB promoter activity (Figure 4e). More-
over, when compared with the mock control, monocyte prolifera-
tion was enhanced by YA-CM (Figure 4f). YA-CM also signiﬁcantly
modiﬁed actin cytoskeleton organization and cell morphology,
together with an increased ability to promote cell migration
(Figures 4g and h). In comparison, WT-CM did not affect cell
proliferation and had milder effects on monocyte morphology and
migration (Figures 4f–h). Interestingly, endothelial permeability
and T-cell migration were also enhanced using YA-CM
(Supplementary Figure S6). Thus, the YA vGPCR-derived secretome
is likely enriched in factors that promote a stronger proinﬂamma-
tory phenotype than that of WT vGPCR. Our work provides
evidence for the involvement of the vGPCR YGLF motif in the
modulation of both NF-kB and paracrine actions, which might
ultimately impact communication within the tumour microenvir-
onment in KSHV-associated pathologies.
DISCUSSION
KSHV is the causative agent for both KS and two forms of high-
grade non-Hodgkin’s lymphomas, namely PEL and multicentric
Castleman disease. Although vGPCR has emerged as a major viral
actor in KS pathogenicity in endothelial cells, its role in infected
B-lymphocytes still needs to be elucidated. In addition, how
vGPCR evades negative feedback loops that normally curtail
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activated GPCRs is an open question. Here, we found that vGPCR
expression contributes to constitutive NF-kB activation in
B-lymphocytes, either from PEL cell lines or from lymphoma-free
KS patients. We further identiﬁed a unique YGLF motif in the
vGPCR C-terminus domain that adjusts its trafﬁcking, NF-kB
signalling activity and paracrine actions.
Su
rfa
ce
To
ta
l
Ig EP
S1
5v
AP2α
AP2α
vGPCR
CHC
EPS15
in
pu
t
vG
PC
R
GST-PD
CX
CR
2
Tubulin
EPS15
Coom.
Surface vGPCR Total vGPCR
β-actin
vGPCR
AU
5
YAW
T
vGPCR
AP2α
IP AU5
AU
5
YAW
T
0
10
4°C 37°C
20
30
40
WT
YA
vG
PC
R 
up
ta
ke
(%
 of
 t t
ran
sfe
cte
d c
ell
s)
YA
W
T
Ig vGPCR
vGPCR
+EPS15DN
Surface vGPCR Total vGPCR
Ig sic AP2α si vGPCR AP2α merge
IP
EPS15
input
Su
rfa
ce
vG
PC
R
To
ta
l
vG
PC
R
Ig
WT
YA
Ig
WT
YA
**
vGPCRCXCR2
Ig
Unst.
+IL8
Ig
Unst.
vGPCR AP2α merge
vGPCR EPS15 merge
100
80
60
40
20
0
100 101 102 103
100
80
60
40
20
0
100 101 102 103 104
100
80
60
40
20
0
100 101 102 103 104
100
80
60
40
20
0
100 101 102 103 104
104
100
80
60
40
20
0
100 101 102 103 104
100
80
60
40
20
0
100 101 102 103 104
100
80
60
40
20
0
100 101 102 103 104
100
80
60
40
20
0
100 101 102 103 104
100
80
60
40
20
0
100 101 102 103 104
100
80
60
40
20
0
100 101 102 103 104
4°C 37°C
AP2α
Tubulin
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expression before (unst.) and after IL-8 stimulation (þ IL-8, 50 ng/ml, 30min). Dashed histograms correspond to the isotype-matched control
(Ig) and grey histograms show antibody (Ab) staining of 10 000 events. (b) BC3 cells were costained for vGPCR and either AP2a or EPS15 and
further processed for confocal microscopy. Scale bars: 10 mm. (c) EPS15 immunoprecipitations were performed in BC3 cells. Interactions with
CCV components were detected using antibodies against AP2a and clathrin heavy chain (CHC). In addition, vGPCR expression was analysed
by western blots. Immunoglobulins (Ig) were used as a negative control. (d) HeLa protein lysates (input) were incubated with GST-tagged
vGPCR and CXCR2 C-tails. EPS15 and AP2a expression was assessed by western blots. Tubulin was used a loading control. Levels of
recombinant proteins were controlled by Coomassie Blue staining (Coom.). (e) BC3 cells were nucleofected with either non-silencing duplexes
sequence (sic) or AP2a siRNA (AP2a si) for 72 h. siRNA efficiency was estimated by western blots against AP2a. Tubulin serves as a loading
control. BC3 cells were stained with vGPCR and analysed by flow cytometry (10 000 events). Ig corresponds to the isotype-matched control.
(f ) HeLa cells were transfected with mock, a dominant-negative EPS15-GFP form (EPS15dn), vGPCR or both EPS15dn and vGPCR constructs.
Cells were analysed 24 h post-transfection using flow cytometry. Dashed histograms correspond to the isotype-matched control, grey and
black histograms show monoclonal Ab staining of 10 000 events. (g) HeLa cells were transfected with vGPCR, costained for both vGPCR and
AP2a, and then processed for confocal microscopy. Scale bars: 10 mm. (h) vGPCR expression levels were analysed by reverse transcription–PCR
(RT–PCR) in HeLa cells transfected with AU5-tagged WT or YA vGPCR. An empty AU5 plasmid (AU5) was used as a control. AU5
immunoprecipitation (IP) fractions from HeLa cells transfected with AU5, AU5-tagged WT or YA vGPCR were assessed by western blots against
vGPCR and AP2a. (i) HeLa cells were transfected with AU5, AU5-tagged WT or YA vGPCR and were analysed for total or surface vGPCR
expression by flow cytometry. Dashed histograms correspond to the isotype-matched control (Ig), grey and black histograms show vGPCR
staining of 10 000 events. (j) HeLa cells transfected with AU5-tagged WT or YA vGPCR were incubated with anti-vGPCR antibodies for 1 h at
4 1C (total) followed by 25min incubation at 37 1C (uptake) before fixation. Scale bars: 10 mm. Graph represents the ratio between the number
of cells with internal staining and the total number of transfected cells. n4200, unpaired t-test: **Po0.01. Pearson’s coefficient was measured
using the Image J plugin. Each panel is representative of three independent experiments.
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vGPCR resembles the IL-8 receptor CXCR2, which operates as a
potent chemoattractant for T-lymphocytes and neutrophils, and
displays high angiogenic properties.42 These pleiotropic functions
ascribed to CXCR2 require strict control to avoid adverse effects in
the organism. By contrast, vGPCR has evolved in a way that the
viral receptor can be activated either upon ligand binding or in a
ligand-independent manner, thereby exhibiting uninterrupted
and constitutive activation.25,26,31 When compared with the
CXCR2 sequence and even to those of other human chemokine
receptors, vGPCR exhibits multiple substitutions in key residues
involved in conformational changes and G-protein coupling.27,37
Here, we report the identiﬁcation of a classical AP2 binding motif
(Y326GLF) within the intracellular C-terminus domain, unique to
vGPCR. This site is indeed absent from human CXCR1, CXCR2 and
CXCR4, and other viral GPCRs, namely BILF1 in EBV (Epstein–Barr
virus), U12 and U51 in HHV-6A/B and HHV-7, and U27, U28, UL33
and UL78 in HCMV (human cytomegalovirus). Our results strongly
support the idea that this motif is functional and drives vGPCR
shuttling between the plasma membrane and CCV (Figure 3).
Although we demonstrated that the YGLF motif is essential for
vGPCR trafﬁcking and downstream NF-kB activation, other key
functions, including G-protein coupling, b-arrestin interaction,
tyrosine sulfation and phosphorylation by GRKs remain to be
investigated. Under physiological circumstances, GPCR missions
are mainly terminated by internalization in CCV, where they can
follow different fates: (i) fast targeting to lysosomes, (ii) rapid
recycling back to the plasma membrane or (iii) retention in
endosomes for a slow degradation or recycling process. The
presence in the vGPCR C terminus domain of a binding motif for
AP2, an integral CCV component, raises questions. One could
imagine that because vGPCR is constitutively active, it has to evade
physiological processes involved in desensitization. In this scenario,
by constantly trafﬁcking in CCV, vGPCR could escape stop signals
normally operating on agonist-activated GPCRs. Accordingly,
abrogation of the Y326GLF motif stabilizes vGPCR at the plasma
membrane. Unexpectedly, rather than normalization, the expres-
sion of the YA vGPCR mutant enhances the activation of NF-kB
(Figure 4).
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Figure 4. Abrogation of the YGLF motif alters NF-kB activation and vGPCR paracrine actions. (a) HeLa cells transfected with WT or YA vGPCR
were analysed by flow cytometry for total vGPCR and pIkBa expression. Dashed histograms correspond to the isotype-matched control (Ig),
grey and black histograms show antibody staining of 10 000 events. (b) NF-kB promoter activity was determined by a luciferase reporter assay
in HEK-293T cells transfected with the indicated amounts of DNA of either WT or YA vGPCR constructs. Graph represents the mean±s.d. from
three experiments, unpaired t-test: ***Po0.001. (c) Cytokine profile as determined using reverse transcription–PCR (RT–PCR) on mRNA from
HeLa cells transfected with either AU5-tagged WT or YA vGPCR constructs. Statistical analysis was conducted using the PRISM statistical
software, using an unpaired t-test: **Po0.01, *Po0.05. (d) vGPCR expression was detected by reverse transcription–PCR (RT–PCR) in HeLa cells
transfected with WT or YA vGPCR. b-Actin serves as a control. (d–h) THP1 monocytes were treated with CM collected from HeLa cells 24 h after
transfection with AU5, WT vGPCR or YA vGPCR constructs. (d) FACS analysis of pIkBa expression. Dashed histograms correspond to the
isotype-matched control, grey and black histograms show antibody staining of 10 000 events. (e) NF-kB promoter activity was determined by
a luciferase reporter assay in THP1-Lucia monocytes. Graph represents the mean±s.d. from three experiments normalized to untreated cells,
unpaired t-test: *Po0.05. (f ). THP1 cells were treated for 72 h and manually counted. Statistical analysis was conducted using the PRISM
statistical software using a two-tailed unpaired t-test: **Po0.01. (g) THP1 cells treated for 72 h were stained with phalloidin and
counterstained with DAPI. Actin morphology was examined by confocal microscopy. (h) THP1 migration was monitored in the presence of
indicated CM for 3 h. Statistical analysis was conducted using two-tailed unpaired t-test: **Po0.01, ***Po0.001. Each panel is representative of
three independent experiments.
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As many transforming abilities of vGPCR rely on NF-kB activity
and paracrine signalling,16 what could be the beneﬁt for the virus
to select a less active form? Cesarman and co-workers35 have
demonstrated that enforced expression of vGPCR augments not
only NF-kB activity in PEL cells but also cell death, suggesting that
exacerbated vGPCR signalling activity does not provide any
selective advantage. In addition, the YA vGPCR-mediated
elevated NF-kB activity was associated with an excessive
inﬂammatory phenotype, as illustrated by cytokine production,
monocyte and T-lymphocyte migration, monocyte spreading and
proliferation, and endothelial permeability (Figure 4 and
Supplementary Figure S6). It is worth noting that GPCRs exploited
by other human viruses (as listed above) also mimic human
receptors and foiled immune responses.37 Therefore, strategies
aimed at stabilizing vGPCR at the plasma membrane and blocking
its low but constant cycling in CCV might be envisaged to raise an
adapted immune response towards infected cells.
In this regard, B-lymphocytes could serve as a reservoir for KSHV,
in both KS and lymphomas.4,43,44 From a molecular standpoint,
many signalling cascades downstream of vGPCR were found to
be shared between B-lymphocytes and endothelial cells, including
Ga-independent NF-kB activation.13,31,45 However, the exact
molecular route that turns on NF-kB in vGPCR-expressing cells is
still under question. Importantly, we report here that primary B cells
from KS patients exhibited high levels of NF-kB activation, even in a
lymphoma-free context, whereas their survival is reduced upon
vGPCR silencing (Figures 1 and 2). Selective expression of vGPCR in
endothelial cells provokes inﬂammatory angiogenic KS-like lesions,
where vGPCR-driven NF-kB activation may also have a role in
tumour initiation and paracrine propagation.13,16,20,28 Although it is
established that PEL are highly dependent on NF-kB activation and
that vFLIP might recapitulate this addiction,11,17,22 our study now
expands the possibility that cancerous and non-cancerous KSHV-
infected B-lymphocytes co-opt vGPCR. Indeed, we show that both
vFLIP and vGPCR are independently involved in NF-kB activation
(Supplementary Figure S4). This argues in favour of a multi-
parametric action of vGPCR in infected cells that is dependent on
an intricate crosstalk between viral products, the host and the
microenvironment.
In conclusion, KSHV-associated malignancies remain life-threa-
tening cancers. The KSHV genome contains several pirated
versions of cellular genes that are involved in cell cycle control,
apoptosis blockade and paracrine/autocrine signalling, with
vGPCR being one of its most prominent viral oncogenes. Further
understanding of the molecular mechanisms of vGPCR in infected
cells and in the tumour microenvironment will be beneﬁcial to the
development of new therapies for treating KSHV-governed
diseases.
MATERIALS AND METHODS
Antibodies and reagents
Antibodies against CD19, CD11, CD14, CD3, CXCR2 and LAMP2, respective
IgG isotype controls, phycoerythrin-conjugated rat anti-mouse IgG2aþ b,
AP2a, clathrin heavy chain and the Perm/Wash kit were obtained from BD
(Le Pont de Claix, France). The following antibodies were used: IkBa,
phospho-IkBa S32, phospho-IkBa S32/S36, phospho-NF-kB S536, GM130
and cleaved caspase-3 (Cell Signaling, Boston, MA, USA), EPS15, tubulin
and NF-kB p65 (Santa Cruz, Heidelberg, Germany), AU5 (Covance,
Rueil-Malmaison, France), kinectin (Millipore, St Quentin en Yvelines,
France), LNA (Novocastra, Nanterre, France), vGPCR KSHV/HHV-8 ORF74
(R&D Systems, Lille, France) and RTA KSHV/HHV-8 ORF50 (antibodies
online). AlexaFluor488 phalloidin, DIOC6, ProLong Gold Antifade Covance
reagent with DAPI (4,6 diamidino-2-phenylindole) and secondary anti-
bodies were obtained from Life Technologies (Saint Aubin, France). IL-8
was obtained from Peprotech (Neuilly-sur-Seine, France). IkB kinase
inhibitor BMS-345541 (1.56–6.5mM, 48 h) and phorbol 12-myristate
13-acetate (10 ng/ml, 48 h) were from Sigma (Lyon, France).
Ethics statement
HIV-negative, KSHV-positive (Table 1) and HIV-negative, KSHV-negative
patients were followed by ND in the Dermatology Service (Cochin Hospital,
Pavillon Tarnier, Paris, France). They all signed a written informed consent
before sample collection, which occurred when providing a routine blood
sample for diagnostic purposes. This study abides the rules of the Helsinki
Protocol.
PBMCs isolation and puriﬁcation
Fresh PBMCs were isolated using standard Ficoll-hypaque density
centrifugation protocol (Ficoll-Paque; GE Healthcare, Velizy-Villacoublay,
France). CD19-positive cells were puriﬁed by negative selection using
magnetic cell sorting kit (Naive B cell isolation kit II; Miltenyi, Paris, France).
Cell culture, transfections and siRNA
BC3, BJAB, THP1, HeLa, Jurkat E6.1 and HEK-293T cells were purchased
from ATCC (Molsheim, France). BC1, BCBL1 and CROAP/6 were obtained
from DMSZ (Braunschweig, Germany) and THP1-Lucia NF-kB cells from
Invivogen (Toulouse, France). Human umbilical vein endothelial cells were
maintained as described previously.33 DNA and siRNA were transfected
using Turbofect (Fermentas, St Leon Rot, Germany) and Lipofectamine
RNAiMax (Life Technologies), respectively. Alternatively, BC3 cells, total
PBMCs and puriﬁed CD19-positive cells were nucleofected (Amaxa, Basel,
Switzerland). CM were collected 24 h post-transfection and cleared by
centrifugation and ﬁltration. Non-silencing duplexes, predesigned MISSION
siRNA sequences targeting human AP2a (EHU089461), duplexes designed
against vGPCR (no. 1: 50-UCUCAUAACACAUGGCCUG-30 and no. 3:
50-UCUGACAUGCAGUCGCCAG-30) and vFlip (50-AACGUGUUCAUACCUCAA
CCC-30) were purchased from Sigma.
DNA constructs
pCEFL-AU5 WT vGPCR construct,33 pCEFL-AU5 R143A vGPCR construct,46
pCEFL-HA-vFLIP20 and pEGFP D95/295 deletion mutant Eps15 (EPS15dn)
construct47 were described previously. The vGPCR Y326A mutant was
generated in pCEFL-AU5 backbone using site-directed mutagenesis (PFU
Ultra; Life Technologies) and conﬁrmed by sequencing (Beckman Coulter
Genomics, Takeley, UK). vGPCR and human CXCR2 intracellular C-terminal
tails (amino acids 321–342 and 321–360, respectively) were cloned in-
frame into pGEX2-4 T plasmid between EcoRI and NotI.
Flow cytometry
For cell surface markers, cells were stained following an indirect (vGPCR) or
direct (CD19, CD11, CD14, CD3 and CXCR2) immunoﬂuorescence protocol.
For intracellular staining (pS32-IkBa, RTA and LNA), cells were ﬁxed using
1% paraformaldehyde and permeabilized by resuspension and vortexing
in ice-cold methanol. Cells were incubated with primary antibodies,
washed three times with cold phosphate-buffered saline and stained with
the corresponding Alexa488- or phycoerythrin-conjugated IgG. For total
vGPCR/CXCR2 staining, cells were ﬁrst incubated with anti-vGPCR/CXCR2
antibodies, ﬁxed in 1% paraformaldehyde, permeabilized with the Perm/
Wash kit (BD) and processed for a second incubation with anti-vGPCR
antibodies. For cell viability measurement, cells were incubated with DIOC6
(40 nM, 10min, 37 1C) and immediately analysed by ﬂow cytometry. Data
were acquired on a FACScalibur (equipped with CellQuest software; BD)
and processed with FlowJo (Ashland, OR, USA).
NF-kB luciferase reporter assay
NF-kB promoter activity was performed as described elsewhere48 using the
Dual-Luciferase Kit (Promega, Madison, WI, USA). Fireﬂy ﬂuorescence units
were normalized to Renilla luciferase ﬂuorescence units.
Western blots, GST pull-downs and immunoprecipitations
EPS15 and AU5 immunoprecipitations were performed as previously
described.33 For GST pull-downs, GST-fused peptides corresponding to
CXCR2321–360 and vGPCR321–342 were afﬁnity-puriﬁed on glutathione beads
(Life Technologies), and incubated for 2 h with HeLa cell protein lysates,
washed ﬁve times and analysed by western blot. Equal amounts of protein
lysates, IP and GST fractions were separated onto 4–20% polyacrylamide
Nupage gels (Life Technologies). Membranes were scanned using the
Odyssey Infra-Red Imaging System (Li-Cor BioSciences, Lincoln, NE, USA).
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Reverse transcription–polymerase chain reaction
RNA was extracted (Qiagen RNeasy Mini Kit) and equal amounts were
reverse transcribed using the Superscript III RT kit (Life Technologies).
Resulting cDNA was used to amplify vGPCR, LNA, vFLIP, vCyclin, vIL6,
vCCL2, vIRF2, RTA, vOX2 and human IL-6, IL-8, IL-12a, IL-15, tumor growth
factor-b and b-actin. mRNA was generated by polymerase chain reaction
(PCR) in the presence of RedTaq Ready Mix (Sigma) using speciﬁc primer
sets (Supplementary Table S3).
THP1 migration, proliferation and viability
Cell migration was determined with a 24-well Boyden chamber using a
polyvinyl pyrrolidone-free polycarbonate ﬁlter with an 8mm pore size
(Nunc, Rochester, NY, USA) as described previously.49 Cells that migrated
into the CM-containing lower chamber were collected after 3 h and the cell
number was manually counted in triplicate for each condition in four
independent experiments. Proliferation was estimated by manual counts
in THP1 (5 104) treated with CM for 72 h, and in triplicate for each
condition in four independent experiments. Viability was evaluated with
MTT (Sigma) and Uptiblue (Interchim, Montlucon, France), according to the
manufacturer’s instructions.
Immunoﬂuorescence, Internalization assay and confocal
microscopy
For HeLa cell imaging, staining was performed on cells grown on collagen-
coated glass coverslips. For BC3 and THP1, cells were placed on poly-D-
lysine-coated slides.33 Internalization assay and immunoﬂuorescence were
conducted as described previously.33 Cells were then mounted and
analysed by confocal microscopy (TCS/SP5 Leica confocal microscope,
Leica, Nanterre, France). Pearson’s coefﬁcient was measured using the
Image J plugin (NIH, Besthesda, MD, USA).
Statistical analysis
All statistical analysis was performed using Graphpad Prism version 5.0c.
Statistical analysis were carried out using one-way analysis of variance,
two-way analysis of variance and an unpaired two-tailed t-test, as speciﬁed.
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